Form 4: IRADIMED CEO Sells Shares Under 10b5-1 Plan

IRADIMED CEO Roger E. Susi sold 4,900 shares of common stock on October 1, 2025, through a pre-arranged 10b5-1 trading plan.

Summary

• Roger E. Susi, who serves as CEO, President, Chairman, Director, and 10% Owner of IRADIMED CORP (IRMD), reported sales of common stock.
• Transactions occurred on October 1, 2025, involving the disposition of 4,900 shares of common stock.
• The sales were executed in three separate transactions at weighted average prices of $69.20, $70.41, and $71.03 per share.
• These sales were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Roger E. Susi on June 16, 2025.
• Following these transactions, indirect beneficial ownership by the Phillip Susi 2008 Dynasty Trust stands at 2,347,500 shares.
• Indirect beneficial ownership by the Roger E. Susi Revocable Trust remains at 162,950 shares.
• Indirect beneficial ownership by the Matthew Susi 2008 Dynasty Trust is 2,062,500 shares, with Roger E. Susi disclaiming beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 4

Explanation: The CEO's sale of shares, while executed under a pre-arranged 10b5-1 plan, represents a reduction in direct beneficial ownership, which can be interpreted cautiously by investors. The pre-planned nature mitigates, but does not eliminate, potential negative sentiment.

Positives

• The sales were executed pursuant to a Rule 10b5-1 trading plan, indicating the transactions were pre-scheduled and not based on new, non-public information, which can mitigate concerns about opportunistic insider selling.

Negatives

• Roger E. Susi, the CEO, President, and Chairman, sold a total of 4,900 shares of common stock, representing a reduction in his direct beneficial ownership.

Risks

• Potential negative market perception due to significant insider selling by the CEO, which could be interpreted by some investors as a signal about the stock's valuation or future prospects.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Indirect beneficial ownership is held through the Phillip Susi 2008 Dynasty Trust (2,347,500 shares).
• Indirect beneficial ownership is held through the Roger E. Susi Revocable Trust (162,950 shares).
• Indirect beneficial ownership is held through the Matthew Susi 2008 Dynasty Trust (2,062,500 shares), with beneficial ownership disclaimed except for pecuniary interest.

Stakeholder Impact

• Shareholders may interpret the CEO's share sales as a signal regarding the company's valuation or future prospects, potentially influencing trading decisions.

Key Dates

Recommendation

The CEO's sale of shares, while notable, was conducted under a pre-arranged 10b5-1 trading plan, which suggests a planned liquidity event rather than a reaction to new, undisclosed negative information. Investors should monitor future filings and company performance, but this specific transaction alone does not warrant a strong buy or sell recommendation.

Keywords

IRADIMED, IRMD, Form 4, insider trading, stock sale, Roger E. Susi, 10b5-1 plan, CEO, director, beneficial ownership